Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Cannabis Bioscience International Holdings Debt-to-Equity?
Cannabis Bioscience International HoldingsCBIH Debt-to-Equity is -0.28 as of Feb. 2026. The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Cannabis Bioscience International Holdings ranks worse than 123304.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cannabis Bioscience International Holdings Debt-to-Equity Related Terms
Cannabis Bioscience International Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings Debt-to-Equity Chart
Cannabis Bioscience International Holdings Annual Data
CBIH vs SKYI, CBDY, NPHC: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Bioscience International Holdings Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings (CBIH) has a Debt-to-Equity of -0.28 as of Feb. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cannabis Bioscience International Holdings and its competitors. According to the industry distribution chart, Cannabis Bioscience International Holdings ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is Cannabis Bioscience International Holdings' Debt-to-Equity too high?
Cannabis Bioscience International Holdings' current Debt-to-Equity is -0.28. Based on the distribution chart, Cannabis Bioscience International Holdings ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cannabis Bioscience International Holdings' Debt-to-Equity compare to SKYI and CBDY?
According to the Drug Manufacturers industry distribution chart, Cannabis Bioscience International Holdings ranks #999999 out of 811 companies for Debt-to-Equity. This places Cannabis Bioscience International Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cannabis Bioscience International Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Bioscience International Holdings's current Debt-to-Equity is -0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current Debt-to-Equity of -0.28. The current Debt-to-Equity is -0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current Debt-to-Equity is -0.28 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIH has been successfully added to your 
